Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature-Reference-Cited by-同舟云学术

Atorvastatin favorably modulates a clinical hepatocellular carcinoma risk gene signature

Published:2022-06-16 Issue:9 Volume:6 Page:2581-2593
ISSN:2471-254X
Container-title:Hepatology Communications
language:en
Short-container-title:Hepatology Communications

Author:

Kim Myung‐Ho¹,Kim Mi‐Young¹²³,Salloum Shadi¹,Qian Tongqi⁴,Wong Lai Ping⁵⁶,Xu Min¹,Lee Yoojin¹,Shroff Stuti G.⁷,Sadreyev Ruslan I.⁵⁷,Corey Kathleen E.¹^ORCID,Baumert Thomas F.⁸⁹,Hoshida Yujin⁴,Chung Raymond T.¹

Affiliation:

1. Liver Center Gastrointestinal Division Massachusetts General Hospital Boston Massachusetts USA

2. Department of Gastroenterology CHA Bundang Medical Center CHA University School of Medicine Seongnam South Korea

3. Department of Gastroenterology, Chaum Life Center CHA University School of Medicine Seoul South Korea

4. Liver Tumor Translational Research Program Simmons Comprehensive Cancer Center Division of Digestive and Liver Diseases Department of Internal Medicine University of Texas Southwestern Medical Center Dallas Texas USA

5. Department of Molecular Biology Massachusetts General Hospital Boston Massachusetts USA

6. Department of Genetics Harvard Medical School Boston Massachusetts USA

7. Department of Pathology Massachusetts General Hospital and Harvard Medical School Boston Massachusetts USA

8. Institut National de la Santé et de la Recherche Médicale U1110 Institut de Recherche sur les Maladies Virales et Hépatiques Strasbourg France

9. Pole Hepato‐digestif, IHU Strasbourg University Hospitals Strasbourg France

Funder

Cancer Prevention and Research Institute of Texas

European Commission

Fondation ARC pour la Recherche sur le Cancer

National Cancer Institute

National Institute of Allergy and Infectious Diseases

National Institute of Diabetes and Digestive and Kidney Diseases